Prelude Therapeutics Files 8-K with Exhibits
Ticker: PRLD · Form: 8-K · Filed: Apr 20, 2026 · CIK: 0001678660
Sentiment: neutral
Topics: disclosure, regulatory-filing, exhibits
TL;DR
Prelude Therapeutics filed an 8-K on 4/20/2026 with various exhibits, likely containing important company updates.
AI Summary
On April 20, 2026, Prelude Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The filing includes various exhibits, such as an iXBRL 8-K and numerous graphic files, likely related to presentations or data visualizations.
Why It Matters
This filing provides an update on Prelude Therapeutics' corporate activities and financial reporting, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain immediate negative or positive material news.
Key Players & Entities
- Prelude Therapeutics Inc. (company) — Filer of the 8-K report
- 0001678660 (company) — CIK number for Prelude Therapeutics Inc.
- 0001193125-26-162620 (filing_id) — SEC Accession Number for the 8-K filing
- 2026-04-20 (date) — Filing Date and Period of Report
FAQ
What specific information is contained within the exhibits attached to this 8-K filing?
The filing lists exhibits including an iXBRL 8-K (d135229d8k.htm) and numerous graphic files (e.g., g135229ex99_2s10g1.jpg), suggesting presentations or data visualizations, but the specific content is not detailed in the provided summary.
What are the main items covered by this 8-K filing?
This 8-K filing covers Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).
When was this 8-K filing accepted by the SEC?
The filing was accepted by the SEC on 2026-04-20 at 06:16:38.
What is the purpose of an 8-K filing?
An 8-K filing is used by publicly traded companies to disclose material events that shareholders should know about, such as acquisitions, bankruptcy, or changes in leadership.
Does this filing indicate any new financial results for Prelude Therapeutics?
While Item 9.01 covers Financial Statements and Exhibits, the provided text does not detail specific financial results; it only indicates the inclusion of exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 20, 2026 regarding Prelude Therapeutics Inc (PRLD).